Theorem Clinical Research Expands its Cardiovascular Expertise Through Alliance With BioTelemetry


Company News Release

Theorem Clinical Research has announced the formation of a strategic alliance with BioTelemetry, Inc.

Theorem Clinical Research

, a clinical research organization specializing in complex trials, has announced the formation of a strategic alliance with BioTelemetry, Inc. (Nasdaq: BEAT). BioTelemetry’s Clinical Research division includes Cardiocore, a global cardiac core laboratory.

“Theorem’s business strategy is to offer our clients the very best in every service area,” said

John Potthoff

, Theorem president and CEO. “BioTelemetry reinforces that strategy with a team of industry-leading scientists, a set of advanced technologies and a broad base of cardiac testing modalities. Theorem clients will benefit from BioTelemetry’s expert consulting services and deep experience across all major therapeutic areas.”


CEO Joseph Capper noted, “Theorem’s experience in complex protocols aligns perfectly with our specialized cardiovascular testing services. The partnership complements BioTelemetry’s unique position that spans from clinical research through post-market surveillance and into clinical practice. Both companies support trials in

all clinical phases

of pharmaceutical and biotech development and will collaborate globally within this alliance.”

“Trends in the industry such as safety monitoring boards, translational medicine and risk-based monitoring put additional pressures on the clinical trial process to be faster, safer and more efficient,” said Potthoff. “Our strategic partnership with BioTelemetry allows us to meet — and exceed — those industry standards for our clients.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.